TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21121983
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 μg/day
Study: 12375667
Drug: G-CSF (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (3 microg/kg) plus dexamethasone (8 mg orally)
Study: 12375667
Drug: G-CSF (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (12 microg/kg) alone
Study: 12622856
Drug: Braun Oral-B
Normalized name: bran Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral-B 3D Plaque Remover
Study: 29862269
Drug: Conventional implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implants
Study: 25479585
Drug: Nafamostat mesilate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nafamostat mesilate 20 mg in 500 mL of 5% glucose solution
Study: 25479585
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (500 mL of 5% glucose solution)
Study: 2654259
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg daily (N = 37)
Study: 25488124
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (2.0 mg)
Study: 15489091
Drug: Renal insufficiency
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal insufficiency categorized as creatinine clearance (CrCl) <40 ml/min
Study: 15489091
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (users)
Study: 15489091
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (nonusers)
Study: 2876723
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg levocabastine
Study: 2876723
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg disodium cromoglycate (DSCG)
Study: 2786751
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody 260F9‐recombinant ricin A chain (10 micrograms/kg daily)
Study: 2786751
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody 260F9‐recombinant ricin A chain (10 micrograms/kg and 50 micrograms/kg)
Study: 2786751
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody 260F9‐recombinant ricin A chain (50 micrograms/kg)
Study: 25470888
Drug: Lidocaine (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (group L)
Study: 28914415
Drug: Warfarin maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin maintenance doses
Study: 28914415
Drug: Warfarin loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin loading doses
Study: 30265586
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal (SW)
Study: 23429258
Drug: Steroid withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid withdrawal (SW) in prepubertal patients
Study: 17145137
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg T enanthate
Study: 11833925
Drug: Incredible Years
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incredible Years Parenting Program (8-12 weeks of weekly 2-hour parenting classes)
Study: 9727892
Drug: T600/G12 (troglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: T600/G12 (troglitazone 600 mg + glyburide 12 mg)
Study: 11271239
Drug: FK 506
Normalized name: FK-960
DrugBank: FK-960 (DB06465)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK 506 therapy
Study: 11271239
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A therapy
Study: 28330586
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n=6)
Study: 26060625
Drug: Levonorgestrel 0.75
Normalized name: levonorgestrel 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 0.75 mg given 12 hours apart
Study: 26060625
Drug: Yuzpe regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzpe regimen (ethinyl estradiol 100 μg plus 0.5 mg Levonorgestrel repeated after 12 hours)
Study: 21705296
Drug: Palpation by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation by a sports medicine board‐certified staff physician
Study: 20055196
Drug: Drug-free group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-free group (Control)
Study: 16960118
Drug: Synthetic oligosaccharide-protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic oligosaccharide-protein conjugate vaccine, administered as a single intramuscular injection.
Study: 9586883
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: MTX 1,000 mg/m2 i.v. infused over 24 hours and MP 1,000 mg/m2 i.v. infused over 6 hours
Study: 9586883
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: Low-dose repetitive MTX 30 mg/m2 orally every 6 hours for six doses and i.v. MP
Study: 3280257
Drug: Cephalexin 500
Normalized name: cephalexin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 500 mg po, qid for three extra days (Group A)
Study: 3280257
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral therapy (Group B)
Study: 26016586
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education video game
Study: 9484875
Drug: Amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 500 mg tds
Study: 9014544
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion of propofol (4 micrograms.ml‐1 target blood concentration, increased by 2 micrograms.ml‐1 after 3 min of consciousness not lost)
Study: 9014544
Drug: Manual infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual infusion of propofol (both rates)
Study: 7884236
Drug: Intraoperative pelvic
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative pelvic hyperthermochemotherapy (IOPHC) with 40 micrograms/ml mitomycin C at 45 degrees C for 90 min
Study: 7884236
Drug: IOPHC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOPHC treatment
Study: 2448428
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy with doxorubicin (DOX) and cisplatin (CPDD) for poor responders
Study: 22615342
Drug: Mediterranean diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediterranean diet with low cholesterol intake (<300 mg/d)
Study: 18227981
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia with 1.5 microg/ml/kg/h fentanyl followed by 1.0 microg/ml/kg/h fentanyl
Study: 10551568
Drug: 1.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/kg perflubron emulsion with colloid (total = 450 ml) at FIO2 = 1.0
Study: 10551568
Drug: 0.9 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g/kg perflubron emulsion with colloid (total = 450 ml) at FIO2 = 1.0
Study: 8903371
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU of interferon alfa‐2b thrice weekly for 12 weeks
Study: 8903371
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU of interferon alfa‐2b thrice weekly for 12 weeks
Study: 8903371
Drug: 10 MU
Normalized name: saliva substitute comb no.10 MUCOUS MEM POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 MU of interferon alfa‐2b thrice weekly for 12 weeks
Study: 8903371
Drug: Continued therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued therapy at 3 MU for an additional 12 weeks for nonresponders
Study: 8903371
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose from 3 or 5 MU to 10 MU for nonresponders
Study: 1437036
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution rinse
Study: 2681593
Drug: Other drugs
Normalized name: Other drugs for bile therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other drugs modifying myogenic tone
Study: 18321517
Drug: Naproxen suppository
Normalized name: naproxen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen suppository
Study: 12661806
Drug: Beclomethasone diproprionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone diproprionate (50 microg/puff) with Salbutamol (100 microg/puff) by metered dose inhaler with or without spacer
Study: 9366582
Drug: R‐568 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐568 80 mg
Study: 9366582
Drug: R‐568 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: R‐568 160 mg
Study: 8004841
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg
Study: 17714557
Drug: Preoperative proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative proton pump inhibitor‐based triple therapy (rabeprazole 10 mg, clarithromycin 500 mg, amoxicillin 1,000 mg, twice daily for 7 days)
Study: 17714557
Drug: Postoperative proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative proton pump inhibitor‐based triple therapy (rabeprazole 10 mg, clarithromycin 500 mg, amoxicillin 1,000 mg, twice daily for 7 days)
Study: 17714557
Drug: Postoperative proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative proton pump inhibitor‐based triple therapy (Billroth I)
Study: 17714557
Drug: Postoperative proton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative proton pump inhibitor‐based triple therapy (Billroth II)
Study: 10744143
Drug: gemfibrozil treatment
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gemfibrozil treatment
Study: 2009056
Drug: Chemoendocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoendocrine therapy (specific combinations not detailed)
Study: 2009056
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic therapy (control group)
Study: 7272159
Drug: Twice-daily flurbiprofen
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily flurbiprofen
Study: 30029461
Drug: 8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g/day polydextrose
Study: 30029461
Drug: 12 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 g/day polydextrose
Study: 31732715
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion (0.5 mg/kg) over 40 minutes
Study: 11182190
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) 20 mg tid plus conventional therapy (thrombolytic therapy, aspirin, beta-blocker, heparin, intravenous nitroglycerin)
Study: 11182190
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (thrombolytic therapy, aspirin, beta-blocker, heparin, intravenous nitroglycerin)
Study: 24530385
Drug: Ketoprofen gel
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen gel
Study: 24943961
Drug: Weekly azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly azithromycin for 3 weeks
Study: 22619063
Drug: Week 12
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 12 HCV RNA cutoff of ≥ 100 IU/mL stopping rule
Study: 22619063
Drug: Week 12
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 12 HCV RNA levels between 9.3 IU/mL and 25 IU/mL
Study: 22619063
Drug: Week 12
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 12 HCV RNA level of 148 IU/mL
Study: 22619063
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of stopping rules (HCV RNA level ≥ 100 IU/mL at week 12 and detectable HCV RNA at week 24)
Study: 16970099
Drug: Shufei Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shufei Granule (SG) 10 g 3 times a day orally, in addition to control treatment.
Study: 16970099
Drug: Fleroxacin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 0.2 g twice per day by intravenous dripping and diprophylline 0.2 g 3 times per day orally (Control group).
Study: 12913678
Drug: Anti-oxidant and
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-oxidant and micronutrient therapy
Study: 8694015
Drug: Fungal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fungal oil (3.6 g AA, 2.9 g DHA)
Study: 8694015
Drug: Fungal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fungal oil (0 g AA, 0 g DHA)
Study: 8694015
Drug: Fungal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fungal oil (0.8 g AA, 0.6 g DHA)
Study: 30384375
Drug: Palosuran 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palosuran 500 mg b.i.d.
Study: 27260129
Drug: Doxazosin 4
Normalized name: doxazosin 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 4 mg and tolterodine ER 4 mg per day
Study: 27260129
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg and tolterodine ER 4 mg per day
Study: 17654694
Drug: Levodopa 100
Normalized name: levodopa 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg t.i.d. with sarizotan 5 mg b.i.d.
Study: 17654694
Drug: Levodopa 100
Normalized name: levodopa 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg t.i.d. without sarizotan
Study: 8087189
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) 10 mg
Study: 26821045
Drug: Oral exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral exposure duration of 8 min
Study: 26821045
Drug: Oral exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral exposure duration of 1 min
Study: 17118686
Drug: Budesonide/formoterol pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol pMDI 160/4.5 microg, two inhalations twice daily
Study: 17118686
Drug: Budesonide/formoterol DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol DPI 160/4.5 microg, two inhalations twice daily
Study: 16544967
Drug: Minoxidil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minoxidil (5 mg)
Study: 1363892
Drug: New drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drugs (Navelbine, taxol, campthotecine) for NSCLC chemotherapy
Study: 1363892
Drug: Dose intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose intensity improvement with growth factors for SCLC
Study: 1363892
Drug: Fractionation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionation of therapy for SCLC
Study: 11863478
Drug: Transferrin receptor-ferritin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transferrin receptor-ferritin index (TR-F index)
Study: 2268867
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of cefuroxime axetil orally (250 mg q12h)
Study: 2268867
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg of cefuroxime axetil orally (500 mg q12h)
Study: 27527354
Drug: DPBN-16 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPBN-16 Gy (dose range between 14 and 18 Gy)
Study: 25591433
Drug: Ringer lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer lactate solution (RL) group
Study: 23673291
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride (HCl) extended release (ER) tablets (test formulation)
Study: 19514189
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine group (Nimesulide tablets)
Study: 19514189
Drug: Point-injection group
Normalized name: meningococcal group B vaccine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-injection group (Anisodamine injected)
Study: 17339748
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) 0.33 mg/day
Study: 8240477
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream over the proposed epidural site for a minimum period of 5 min (mean 9.1 min)
Study: 8240477
Drug: Skin bleb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin bleb and subcutaneous injection of lignocaine 2% (1 ml)
Study: 2826064
Drug: Oxprenolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxprenolol (80 mg orally)
Study: 20595155
Drug: Ciclesonide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (160 μg s.i.d.)
Study: 18291270
Drug: Two-visit root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-visit root canal therapy with calcium hydroxide/chlorhexidine paste dressing
Study: 16603430
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal preparation
Study: 29284438
Drug: IMPaCT Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPaCT Therapy
Study: 29284438
Drug: IMPaCT Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMPaCT Therapy (>180 min)
Study: 26268913
Drug: Cranberry (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry (500 mg daily for 6 months)
Study: 23384111
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel applied to half of the chest scar for three months
Study: 18327093
Drug: Manidipine 10
Normalized name: manidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine 10 mg and Delapril 30 mg
Study: 8792950
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg and Hydrochlorothiazide 12.5 mg
Study: 6754210
Drug: Multiple-dose Methyldopa
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose Methyldopa
Study: 6754210
Drug: Multiple-dose Propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose Propranolol
Study: 11907636
Drug: Amiodarone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (600 mg/d)
Study: 11907636
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 mg/d)
Study: 9270900
Drug: Quetiapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (300 mg daily)
Study: 9270900
Drug: Haloperidol (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (12 mg daily)
Study: 9270900
Drug: Quetiapine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine (all doses)
Study: 9574474
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy (Group 2, n = 74)
Study: 3342283
Drug: Sustained-release tablets
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablets (T)
Study: 21999623
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg/kg bolus prior to surgery)
Study: 21999623
Drug: Fibrin spray
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin spray (10 mL during surgery)
Study: 21999623
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neither treatment)
Study: 6102677
Drug: Intraventricular gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular gentamicin plus systemic antimicrobial agents
Study: 31067131
Drug: Handgrip isometric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Handgrip isometric training five times weekly
Study: 27564409
Drug: Lesinurad 200
Normalized name: lesinurad 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 200 mg added to allopurinol
Study: 27564409
Drug: Lesinurad 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 400 mg added to allopurinol
Study: 27564409
Drug: Lesinurad 200
Normalized name: lesinurad 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lesinurad 200 mg and 400 mg added to allopurinol
Study: 25829346
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (bevacizumab plus dexamethasone delivery system)
Study: 23891461
Drug: Buprenorphine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine therapy with escitalopram treatment for depressive symptoms
Study: 17074798
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg voriconazole twice daily (BID) (400-mg BID loading doses on the first day), n = 16
Study: 17074798
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg voriconazole twice daily (BID) with methadone